---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066916"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:01:43.483289+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q1 revenue $143.5M (+48% YoY), net income $25.7M; raises FY2025 guidance to $565-585M

## Summary
- Q1 revenue $143.5M (+48% YoY from $96.9M); net income $25.7M ($0.70 diluted EPS), up from $12.2M in Q1 2024.
- Gross margin 61% vs 62% a year ago; operating expenses $60.8M (incl. $8.7M stock comp) vs $47.5M.
- FY2025 revenue guidance raised to $565-585M (from $530-552M), representing ~30% YoY growth at midpoint.
- Cash balance $310.1M as of March 31, 2025; owned 21 aircraft for organ logistics.
- Announced design center and manufacturing facility in Mirandola, Italy; 10 abstracts at ISHLT meeting.

## SEC filing metadata
- accession: 0000950170-25-066916
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017025066916/0000950170-25-066916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017025066916/tmdx-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066916
- JSON: https://secwatch.observer/filing/0000950170-25-066916.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.